Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage
- 20 October 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (45), 19473-19478
- https://doi.org/10.1073/pnas.1003308107
Abstract
In nonneuronopathic type 1 Gaucher disease (GD1), mutations in the glucocerebrosidase gene (GBA1) gene result in glucocerebrosidase deficiency and the accumulation of its substrate, glucocerebroside (GL-1), in the lysosomes of mononuclear phagocytes. This prevailing macrophage-centric view, however, does not explain emerging aspects of the disease, including malignancy, autoimmune disease, Parkinson disease, and osteoporosis. We conditionally deleted the GBA1 gene in hematopoietic and mesenchymal cell lineages using an Mx1 promoter. Although this mouse fully recapitulated human GD1, cytokine measurements, microarray analysis, and cellular immunophenotyping together revealed widespread dysfunction not only of macrophages, but also of thymic T cells, dendritic cells, and osteoblasts. The severe osteoporosis was caused by a defect in osteoblastic bone formation arising from an inhibitory effect of the accumulated lipids LysoGL-1 and GL-1 on protein kinase C. This study provides direct evidence for the involvement in GD1 of multiple cell lineages, suggesting that cells other than macrophages may be worthwhile therapeutic targets.Keywords
This publication has 28 references indexed in Scilit:
- A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1Blood, 2010
- High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher diseaseJournal of Inherited Metabolic Disease, 2010
- Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretomeBlood, 2009
- The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patientsAmerican Journal of Hematology, 2009
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast–osteoblast couplingThe EMBO Journal, 2006
- Glucosylceramide transfer from lysosomes—the missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing dataJournal of Inherited Metabolic Disease, 2006
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences of the United States of America, 2006
- Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapyBlood, 2004
- Inducible Gene Targeting in MiceScience, 1995